Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting, 64313-64314 [2010-26251]
Download as PDF
Federal Register / Vol. 75, No. 201 / Tuesday, October 19, 2010 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
ntp.niehs.nih.gov/, select ‘‘Nominations
to the Testing Program’’).
The NTP invites interested parties to
submit written comments, provide
supplementary information, or present
oral comments at the BSC meeting on
the nominated substances and
preliminary study recommendations
(see ‘‘Request for Comments’’ below).
The NTP welcomes toxicology study
information from completed, ongoing,
or anticipated studies, as well as
information on current U.S. production
levels, use or consumption patterns,
human exposure, environmental
occurrence, or public health concerns
for any of the nominated substances.
The NTP is interested in identifying
appropriate animal and non-animal
experimental models for mechanisticbased research, including genetically
modified rodents and high-throughput
in vitro test methods, and as such,
solicits comments regarding the use of
specific in vivo and in vitro
experimental approaches to address
questions relevant to the nominated
substances and issues under
consideration. Although the deadline
for submission of written comments to
be considered at the BSC meeting is
November 16, 2010 (see ‘‘Request for
Comments’’ above), the NTP welcomes
comments or additional information on
these study nominations at any time.
To facilitate review of the proposed
research project by the BSC and the
public, NTP staff developed a draft
research concept document for the
nomination recommended for study. A
research concept is a brief document
outlining the nomination or study
rationale, and the significance, study
approach, and expected outcome of a
proposed research program tailored for
each nomination. The purpose of a
research concept is to outline the
general elements of a program of study
that would address the specific issues
that prompted the nomination and the
preliminary study recommendations. A
research concept may also encompass
larger public health issues or topics in
toxicology that could be appropriately
addressed through studies on the
nominated substance(s). Draft research
concepts should be available on the BSC
meeting page (https://ntp.niehs.nih.gov/
go/165) by October 19, 2010.
Background Information on the NTP
Board of Scientific Counselors
The BSC is a technical advisory body
comprised of scientists from the public
and private sectors that provides
primary scientific oversight to the NTP.
Specifically, the BSC advises the NTP
on matters of scientific program content,
both present and future, and conducts
VerDate Mar<15>2010
16:24 Oct 18, 2010
Jkt 223001
periodic review of the program for the
purpose of determining and advising on
the scientific merit of its activities and
their overall scientific quality. Its
members are selected from recognized
authorities knowledgeable in fields such
as toxicology, pharmacology, pathology,
biochemistry, epidemiology, risk
assessment, carcinogenesis,
mutagenesis, molecular biology,
behavioral toxicology, neurotoxicology,
immunotoxicology, reproductive
toxicology or teratology, and
biostatistics. Members serve overlapping
terms of up to four years. The BSC
usually meets biannually.
Dated: October 5, 2010.
John R. Bucher,
Associate Director, National Toxicology
Program.
[FR Doc. 2010–26023 Filed 10–18–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Endocrinologic and Metabolic Drugs
Advisory Committee; Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Endocrinologic and
Metabolic Drugs Advisory Committee.
General Function of the Committee: To
provide advice and recommendations to the
Agency on FDA’s regulatory issues.
Date and Time: The meeting will be held
on December 7, 2010, from 8 a.m. to 5 p.m.
Location: FDA White Oak Campus, 10903
New Hampshire Ave., Building 31
Conference Center, the Great Room (rm.
1503), Silver Spring, MD 20993–0002.
Information regarding special
accommodations due to a disability, visitor
parking, and transportation may be accessed
at https://www.fda.gov/AdvisoryCommittees/
default.htm; under the heading ‘‘Resources
for You’’, click on ‘‘White Oak Conference
Center Parking and Transportation
Information for FDA Advisory Committee
Meetings’’.
Contact Person: Paul Tran, Center for Drug
Evaluation and Research, Food and Drug
Administration, 10903 New Hampshire Ave.,
Bldg. 31, rm. 2417, Silver Spring, MD 20993–
0002, 301–796–9001, FAX: 301–847–8540, email: paul.tran@fda.hhs.gov, or FDA
Advisory Committee Information Line, 1–
800–741–8138 (301–443–0572 in the
Washington, DC area), code 3014512536.
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
64313
Please call the Information Line for up-todate information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
announced advisory committee meeting
cannot always be published quickly enough
to provide timely notice. Therefore, you
should always check the Agency’s Web site
and call the appropriate advisory committee
hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On December 7, 2010, the
committee will discuss the safety and
efficacy of new drug application (NDA) 20–
0063, proposed tradename CONTRAVE
(naltrexone HCl/bupropion HCl) extendedrelease tablets, manufactured by Orexigen
Therapeutics, Inc., for the treatment of
obesity and weight management, including
weight loss and maintenance of weight loss
in patients with an initial body mass index
(BMI) of equal to or greater than 30 kilograms
(kg) per square meter, or a BMI equal to or
greater than 27 kg per square meter with one
or more risk factors (e.g. diabetes,
dyslipidemia, or hypertension). The BMI is a
measure of body weight (mass) based on a
person’s weight and height, and is a widelyused tool for doctors in assessing optimum
weights for a patient.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
November 22, 2010. Oral presentations from
the public will be scheduled between
approximately 1 p.m. and 2 p.m. Those
desiring to make formal oral presentations
should notify the contact person and submit
a brief statement of the general nature of the
evidence or arguments they wish to present,
the names and addresses of proposed
participants, and an indication of the
approximate time requested to make their
presentation on or before November 12, 2010.
Time allotted for each presentation may be
limited. If the number of registrants
requesting to speak is greater than can be
reasonably accommodated during the
scheduled open public hearing session, FDA
may conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by November 15, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
E:\FR\FM\19OCN1.SGM
19OCN1
64314
Federal Register / Vol. 75, No. 201 / Tuesday, October 19, 2010 / Notices
persons with physical disabilities or special
needs. If you require special accommodations
due to a disability, please contact Paul Tran
at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/
AboutAdvisoryCommittees/ucm111462.htm
for procedures on public conduct during
advisory committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: October 14, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–26251 Filed 10–18–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0001]
Oncologic Drugs Advisory Committee;
Notice of Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
mstockstill on DSKH9S0YB1PROD with NOTICES
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Oncologic Drugs
Advisory Committee.
General Function of the Committee: To
provide advice and recommendations to the
Agency on FDA’s regulatory issues.
Date and Time: The meeting will be held
on December 2, 2010, from 8 a.m. to 5 p.m.
Location: FDA White Oak Campus, 10903
New Hampshire Ave., Building 31
Conference Center, the Great Room (rm.
1503), Silver Spring, MD 20993–0002.
Information regarding special
accommodations due to a disability, visitor
parking, and transportation may be accessed
at https://www.fda.gov/AdvisoryCommittees/
default.htm; under the heading ‘‘Resources
for You’’, click on ‘‘White Oak Conference
Center Parking and Transportation
Information for FDA Advisory Committee
Meetings’’.
Contact Person: Nicole Vesely, Center for
Drug Evaluation and Research, Food and
Drug Administration, 10903 New Hampshire
Ave., Bldg. 31, rm. 2417, Silver Spring, MD
20993–0002, 301–796–9001, FAX: 301–847–
8533, e-mail: Nicole.vesely@fda.hhs.gov, or
FDA Advisory Committee Information Line,
1–800–741–8138 (301–443–0572 in the
Washington, DC area), code 301–451–2542.
Please call the Information Line for up-todate information on this meeting. A notice in
the Federal Register about last minute
modifications that impact a previously
VerDate Mar<15>2010
16:24 Oct 18, 2010
Jkt 223001
announced advisory committee meeting
cannot always be published quickly enough
to provide timely notice. Therefore, you
should always check the Agency’s Web site
and call the appropriate advisory committee
hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On December 2, 2010, during the
morning session, the committee will discuss
biologics license application (BLA) 125377,
with the proposed trade name Yervoy
(ipilimumab), manufactured by Bristol-Myers
Squibb Company. The proposed indication
(use) for this product is for the treatment of
advanced melanoma in patients who have
received prior therapy. During the afternoon
session, the committee will discuss new drug
application (NDA) 022–405, with the
proposed trade name Zictifa (vandetanib)
Tablets, manufactured by iPR
Pharmaceuticals, Inc., represented by
AstraZeneca Pharmaceuticals LP (authorized
U.S. agent). The proposed indication (use) for
this product is for the treatment of patients
with unresectable (non-operable) locally
advanced or metastatic medullary thyroid
cancer.
FDA intends to make background material
available to the public no later than 2
business days before the meeting. If FDA is
unable to post the background material on its
Web site prior to the meeting, the background
material will be made publicly available at
the location of the advisory committee
meeting, and the background material will be
posted on FDA’s Web site after the meeting.
Background material is available at https://
www.fda.gov/AdvisoryCommittees/Calendar/
default.htm. Scroll down to the appropriate
advisory committee link.
Procedure: Interested persons may present
data, information, or views, orally or in
writing, on issues pending before the
committee. Written submissions may be
made to the contact person on or before
November 16, 2010. Oral presentations from
the public will be scheduled between
approximately 10:30 a.m. and 11 a.m. and
between approximately 3:30 p.m. and 4 p.m.
Those desiring to make formal oral
presentations should notify the contact
person and submit a brief statement of the
general nature of the evidence or arguments
they wish to present, the names and
addresses of proposed participants, and an
indication of the approximate time requested
to make their presentation on or before
November 8, 2010. Time allotted for each
presentation may be limited. If the number of
registrants requesting to speak is greater than
can be reasonably accommodated during the
scheduled open public hearing session, FDA
may conduct a lottery to determine the
speakers for the scheduled open public
hearing session. The contact person will
notify interested persons regarding their
request to speak by November 9, 2010.
Persons attending FDA’s advisory
committee meetings are advised that the
Agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee meetings
and will make every effort to accommodate
persons with physical disabilities or special
needs. If you require special accommodations
PO 00000
Frm 00072
Fmt 4703
Sfmt 4703
due to a disability, please contact Nicole
Vesely at least 7 days in advance of the
meeting.
FDA is committed to the orderly conduct
of its advisory committee meetings. Please
visit our Web site at https://www.fda.gov/
AdvisoryCommittees/AboutAdvisory
Committees/ucm111462.htm for procedures
on public conduct during advisory
committee meetings.
Notice of this meeting is given under the
Federal Advisory Committee Act (5 U.S.C.
app. 2).
Dated: October 14, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special
Medical Programs.
[FR Doc. 2010–26247 Filed 10–18–10; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0487]
Product Development Program for
Interventions in Patients With Severe
Bleeding Due to Trauma or Other
Causes; Public Workshop
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice of public workshop.
The Food and Drug Administration
(FDA) is announcing a 2-day public
workshop entitled ‘‘Product
Development Program for Interventions
in Patients with Severe Bleeding Due to
Trauma or Other Causes.’’ The purpose
of this public workshop is to discuss
possible paradigms for the evaluation of
products indicated for use to stop severe
bleeding. The workshop has been
planned in partnership with the
Department of Health and Human
Services, Office of Public Health and
Science; the National Heart, Lung and
Blood Institute; and the Department of
Defense. The public workshop will
include presentations and panel
discussions by experts from academic
institutions, government agencies, and
industry.
Dates and Times: The public
workshop will be held on December 9,
2010, from 8 a.m. to 5:30 p.m. and
December 10, 2010, from 8 a.m. to
1 p.m.
Location: The public workshop will
be held at the Masur Auditorium, 10
Center Dr., Bldg. 10, Clinical Center,
National Institutes of Health, Bethesda,
MD 20892.
Contact Person: Rhonda Dawson,
Center for Biologics Evaluation and
Research (HFM–302), Food and Drug
Administration, 1401 Rockville Pike,
E:\FR\FM\19OCN1.SGM
19OCN1
Agencies
[Federal Register Volume 75, Number 201 (Tuesday, October 19, 2010)]
[Notices]
[Pages 64313-64314]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-26251]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2010-N-0001]
Endocrinologic and Metabolic Drugs Advisory Committee; Notice of
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Endocrinologic and Metabolic Drugs Advisory
Committee.
General Function of the Committee: To provide advice and
recommendations to the Agency on FDA's regulatory issues.
Date and Time: The meeting will be held on December 7, 2010,
from 8 a.m. to 5 p.m.
Location: FDA White Oak Campus, 10903 New Hampshire Ave.,
Building 31 Conference Center, the Great Room (rm. 1503), Silver
Spring, MD 20993-0002. Information regarding special accommodations
due to a disability, visitor parking, and transportation may be
accessed at https://www.fda.gov/AdvisoryCommittees/default.htm; under
the heading ``Resources for You'', click on ``White Oak Conference
Center Parking and Transportation Information for FDA Advisory
Committee Meetings''.
Contact Person: Paul Tran, Center for Drug Evaluation and
Research, Food and Drug Administration, 10903 New Hampshire Ave.,
Bldg. 31, rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX:
301-847-8540, e-mail: paul.tran@fda.hhs.gov, or FDA Advisory
Committee Information Line, 1-800-741-8138 (301-443-0572 in the
Washington, DC area), code 3014512536. Please call the Information
Line for up-to-date information on this meeting. A notice in the
Federal Register about last minute modifications that impact a
previously announced advisory committee meeting cannot always be
published quickly enough to provide timely notice. Therefore, you
should always check the Agency's Web site and call the appropriate
advisory committee hot line/phone line to learn about possible
modifications before coming to the meeting.
Agenda: On December 7, 2010, the committee will discuss the
safety and efficacy of new drug application (NDA) 20-0063, proposed
tradename CONTRAVE (naltrexone HCl/bupropion HCl) extended-release
tablets, manufactured by Orexigen Therapeutics, Inc., for the
treatment of obesity and weight management, including weight loss
and maintenance of weight loss in patients with an initial body mass
index (BMI) of equal to or greater than 30 kilograms (kg) per square
meter, or a BMI equal to or greater than 27 kg per square meter with
one or more risk factors (e.g. diabetes, dyslipidemia, or
hypertension). The BMI is a measure of body weight (mass) based on a
person's weight and height, and is a widely-used tool for doctors in
assessing optimum weights for a patient.
FDA intends to make background material available to the public
no later than 2 business days before the meeting. If FDA is unable
to post the background material on its Web site prior to the
meeting, the background material will be made publicly available at
the location of the advisory committee meeting, and the background
material will be posted on FDA's Web site after the meeting.
Background material is available at https://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the
appropriate advisory committee link.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person on or before
November 22, 2010. Oral presentations from the public will be
scheduled between approximately 1 p.m. and 2 p.m. Those desiring to
make formal oral presentations should notify the contact person and
submit a brief statement of the general nature of the evidence or
arguments they wish to present, the names and addresses of proposed
participants, and an indication of the approximate time requested to
make their presentation on or before November 12, 2010. Time
allotted for each presentation may be limited. If the number of
registrants requesting to speak is greater than can be reasonably
accommodated during the scheduled open public hearing session, FDA
may conduct a lottery to determine the speakers for the scheduled
open public hearing session. The contact person will notify
interested persons regarding their request to speak by November 15,
2010.
Persons attending FDA's advisory committee meetings are advised
that the Agency is not responsible for providing access to
electrical outlets.
FDA welcomes the attendance of the public at its advisory
committee meetings and will make every effort to accommodate
[[Page 64314]]
persons with physical disabilities or special needs. If you require
special accommodations due to a disability, please contact Paul Tran
at least 7 days in advance of the meeting.
FDA is committed to the orderly conduct of its advisory
committee meetings. Please visit our Web site at https://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for
procedures on public conduct during advisory committee meetings.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 14, 2010.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2010-26251 Filed 10-18-10; 8:45 am]
BILLING CODE 4160-01-P